-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier: Cue Biopharma Reports 50% Overall Response Rate And 88% 12-Month Survival In CUE-101 Trial For HPV+ Cancers

Benzinga·07/16/2025 16:06:52
Listen to the news
  • Additional complete response (CR) observed in patient with multiple tumors
  • Confirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients with low CPS (1-19)
  • 12-month overall survival of 88% and median overall survival (mOS) of 32 months

     

BOSTON, July 16, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today provided a clinical update on its most advanced asset, CUE-101, representative of the CUE-100 series.